Actinium Pharmaceuticals Inc. (Delaware) (ATNM) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Actinium Pharmaceuticals Inc. (Delaware) (NYSE: ATNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.53 (+10.87% 1D, market cap $48.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ATNM ranks #586 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATNM carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M) and SER (Serina Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $48.0M). Among the 5-stock peer group, ATNM leads on earnings multiple (N/A) while ATNM leads on capital efficiency (-35.0% ROIC).
Per ATNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388320), Actinium Pharmaceuticals Inc. (Delaware) generated $90.0K in revenue, -$33.9M in net income, and -$24.7M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 81% of 52W Range • RSI-14 at 61 (BULLISH MOMENTUM)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ATNM currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.19) and Max Pain ($1.61) forces dealer call-delta covering toward $1.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Actinium Pharmaceuticals Inc. (Delaware) (ATNM) surged +10.87% to $1.53, trading at 81% of its 52-week range ($0.74 – $1.72). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an inducement equity award to a newly hired non-executive emplo
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that the first‑in‑huma
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑targeted alpha
Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced encouraging initial cl
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical result
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical results
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX) stock
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ATNM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ATNM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Actinium Pharmaceuticals Inc. (Delaware) (ATNM) ranks #586 by composite RQD confidence (42/100, grade D-) and #755 by equity capitalization ($48.1M). Within this direct 5-issuer industry benchmark cohort, ATNM leads on earnings valuation at N/A trailing P/E, while ATNM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SER currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ATNM at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ATNM
ACTIVE
Actinium Pharmaceuticals Inc. (Delaware) | D- | 42/100 | — | — | -35.0% | +10.87% | $48.1M | Benchmark Subject |
| MREO Mereo BioPharma Group plc | D- | 42/100 | — | — | -35.0% | +1.62% | $48.2M | /mreo-vs-atnm → |
| SER Serina Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | +15.24% | $48.0M | /ser-vs-atnm → |
| ELTX Elicio Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -5.40% | $47.4M | /eltx-vs-atnm → |
| CTOR Citius Oncology Inc. | D- | 39/100 | — | — | -35.0% | -8.20% | $49.2M | /ctor-vs-atnm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actinium Pharmaceuticals Inc. (Delaware) (ATNM) reported GAAP revenue of $90.0K (N/A vs. FY2024 revenue of $0 , and +11.1% cumulative change since FY2023) , GAAP net income of -$33.9M, operating cash flow of -$24.6M, and free cash flow of -$24.7M (+25.4% YoY). On the balance sheet, ATNM closed FY2025 with $51.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $90.0K | -$33.9M | -$24.6M | -$24.7M | $51.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$38.2M | -$33.1M | -$33.1M | $76.9M | — |
| FY2023 (FY) | 2023-12-31 | $81.0K | -$48.8M | -$47.3M | -$47.3M | — | — |
As of 2026-11-01, Actinium Pharmaceuticals Inc. (Delaware) (NYSE: ATNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.53 (+10.87% 1D, market cap $48.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ATNM ranks #586 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATNM carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M) and SER (Serina Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $48.0M). Among the 5-stock peer group, ATNM leads on earnings multiple (N/A) while ATNM leads on capital efficiency (-35.0% ROIC).
Per ATNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388320), Actinium Pharmaceuticals Inc. (Delaware) generated $90.0K in revenue, -$33.9M in net income, and -$24.7M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ATNM last traded at $1.53 (+10.87% on volume of 181,681 shares), positioning the stock +28.57% above its 50-day simple moving average ($1.19) and +36.61% above its 200-day simple moving average ($1.12). Across its 52-week range of $0.74 to $1.72, ATNM sits at the 80.6% percentile with a 14-day RSI of 61.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.34 to $1.72).
Why ATNM Stock surged +10.87% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.